Treeline Biosciences Overview
- Status
- Private
- Latest Deal Type
- Series A
- Latest Deal Amount
- $735M
- Investors
- 7
Treeline Biosciences General Information
Description
Developer of transformative precision medicines for patients intended to treat cancer and other serious conditions. The company is currently operating in stealth mode.
Contact Information
Website
www.treelinebiosciences.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 68 Southfield Avenuesuite 100
- Stamford, CT 06902
- United States
Treeline Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 12-Apr-2021 | $735M | 00000 | 00.000 | Completed | Stealth |
Treeline Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Treeline Biosciences Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Jeffrey Engelman Ph.D | Co-Founder & Chief Scientific Officer | ||
| Joshua Bilenker MD | Co-Founder & Chief Executive Officer |
Treeline Biosciences Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Access Industries | Corporation | Minority | 000 0000 | 000000 0 | |
| Aisling Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Ajax Health | Other | Minority | 000 0000 | 000000 0 | |
| ARCH Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Casdin Capital | Hedge Fund | Minority | 000 0000 | 000000 0 |